JP2009519343A - エンテロスタチンの非吸湿性組成物 - Google Patents

エンテロスタチンの非吸湿性組成物 Download PDF

Info

Publication number
JP2009519343A
JP2009519343A JP2008545763A JP2008545763A JP2009519343A JP 2009519343 A JP2009519343 A JP 2009519343A JP 2008545763 A JP2008545763 A JP 2008545763A JP 2008545763 A JP2008545763 A JP 2008545763A JP 2009519343 A JP2009519343 A JP 2009519343A
Authority
JP
Japan
Prior art keywords
enterostatin
hygroscopic
pharmaceutical composition
acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008545763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519343A5 (enExample
Inventor
ルビン ブイロン
Original Assignee
ハルクネスス プハルマセウティカルス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハルクネスス プハルマセウティカルス,インコーポレイテッド filed Critical ハルクネスス プハルマセウティカルス,インコーポレイテッド
Publication of JP2009519343A publication Critical patent/JP2009519343A/ja
Publication of JP2009519343A5 publication Critical patent/JP2009519343A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2008545763A 2005-12-13 2006-12-12 エンテロスタチンの非吸湿性組成物 Pending JP2009519343A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75020805P 2005-12-13 2005-12-13
PCT/US2006/047516 WO2007070562A2 (en) 2005-12-13 2006-12-12 Non-hygroscopic compositions of enterostatin

Publications (2)

Publication Number Publication Date
JP2009519343A true JP2009519343A (ja) 2009-05-14
JP2009519343A5 JP2009519343A5 (enExample) 2010-02-18

Family

ID=38163490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545763A Pending JP2009519343A (ja) 2005-12-13 2006-12-12 エンテロスタチンの非吸湿性組成物

Country Status (4)

Country Link
US (1) US20070149442A1 (enExample)
EP (1) EP1973557A4 (enExample)
JP (1) JP2009519343A (enExample)
WO (1) WO2007070562A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538233A (ja) * 2010-09-15 2013-10-10 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcアゴニストの製剤および使用方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2018503689A (ja) * 2015-01-27 2018-02-08 フローレンゲイル・エル・エル・シー 治癒性局所用組成物
US10034836B2 (en) 2008-12-03 2018-07-31 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
CA2633180A1 (en) * 2005-12-13 2007-06-21 Harkness Pharmaceuticals, Inc. Methods of treating obesity using enterostatin
WO2008008357A1 (en) * 2006-07-11 2008-01-17 Harkness Pharmaceuticals, Inc. Methods of treating obesity using satiety factors
TWI568447B (zh) * 2009-05-08 2017-02-01 上海泰飛爾生化技術有限公司 具有快速透皮速度的多肽及多肽相關化合物的前藥組合物
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
EP3142644A1 (en) * 2014-05-16 2017-03-22 Vivus, Inc. Orally administrable formulations for the controlled release of a pharmacologically active agent
WO2016196804A1 (en) * 2015-06-04 2016-12-08 Balchem Corporation Hydration control for choline salts
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
CN109890384A (zh) * 2016-09-01 2019-06-14 Jds治疗有限公司 生物素镁组合物和使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63211235A (ja) * 1986-11-20 1988-09-02 シヤーロツテ・エルランソン―アルベルツソン 食欲調節用剤
JP2000204045A (ja) * 1999-01-11 2000-07-25 Calpis Co Ltd 造粒物、その製法及びこれを用いた錠剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275823A (en) * 1989-04-27 1994-01-04 Smith Kline & French Laboratories Ltd. Pharmaceutical compositions
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US20030211967A1 (en) * 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
KR20030017569A (ko) * 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
WO2004060347A2 (en) * 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
EA008829B1 (ru) * 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63211235A (ja) * 1986-11-20 1988-09-02 シヤーロツテ・エルランソン―アルベルツソン 食欲調節用剤
JP2000204045A (ja) * 1999-01-11 2000-07-25 Calpis Co Ltd 造粒物、その製法及びこれを用いた錠剤

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034836B2 (en) 2008-12-03 2018-07-31 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2013538233A (ja) * 2010-09-15 2013-10-10 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcアゴニストの製剤および使用方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9919024B2 (en) 2010-09-15 2018-03-20 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9925231B2 (en) 2010-09-15 2018-03-27 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10232011B2 (en) 2010-09-15 2019-03-19 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2018503689A (ja) * 2015-01-27 2018-02-08 フローレンゲイル・エル・エル・シー 治癒性局所用組成物

Also Published As

Publication number Publication date
US20070149442A1 (en) 2007-06-28
EP1973557A4 (en) 2010-03-03
EP1973557A2 (en) 2008-10-01
WO2007070562A3 (en) 2008-11-27
WO2007070562A2 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
KR20190082834A (ko) 단일-투여량, 즉시-사용가능한 주사용 제제
JP2016172745A (ja) ペプチドの組成物及びその調製方法
WO2003045357A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
JP2009519343A (ja) エンテロスタチンの非吸湿性組成物
CN106999558A (zh) (17‑β)‑3‑氧雄甾‑4‑烯‑17‑基十一酸酯组合物及其制备方法和用途
EA027869B1 (ru) Стабилизированная композиция такролимуса
KR20150036553A (ko) 알칼리화제를 함유하지 않는 라퀴니모드 제형
RS57881B1 (sr) Formulacija solubilizovane kapsule 1,1-dimetiletil [(1s)-1-{[(2s,4r)-4-(7-hloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata
CA2800279A1 (en) Oral dosage forms of bendamustine
JP5836372B2 (ja) ビタミンdの14−エピ−アナログの新しい製剤
JP3070930B2 (ja) 脳血管性疾患治療剤および抗炎症剤
MX2007011250A (es) Inhibidor de la cristalizacion y su uso en capsulas de gelatina.
KR101859200B1 (ko) 모노아세틸디아실글리세롤 화합물의 경구 투여용 조성물 및 고형 제제
UA110211C2 (uk) Нові склади 14-eпi-аналогів вітаміну d
JP2024528195A (ja) ブラジキニンb2受容体拮抗薬を経口投与するための脂質ベースの組成物
JP3748912B2 (ja) オーレオバシジン類の高濃度溶液製剤
KR101819310B1 (ko) 사이클로스포린을 포함하는 약학 조성물
US20200155583A1 (en) Solid oral formulations of amphotericin b
AU3043400A (en) Cyclosporin solution
RU2248205C1 (ru) Лекарственное средство в виде желатиновой капсулы
CA2537480A1 (en) Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -ethyl proprionate and salts thereof
US20210369615A1 (en) Solid oral formulations of amphotericin b
UA112845C2 (uk) Склад 14-eпi-аналогів вітаміну d
WO2025109634A1 (en) Stable pharmaceutical composition of cabozantinib
KR20170078972A (ko) 사이클로스포린을 포함하는 약학 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130115